Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Amneal Pharmaceuticals (AMRX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Amneal Pharmaceuticals is one of 984 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).Within the past quarter, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 4.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Our latest available data shows that AMRX has returned about 1.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.5%. This means that Amneal Pharmaceuticals is performing better than its sector in terms of year-to-date returns.Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX). The stock has returned 18.8% year-to-date.In Boston Scientific's case, the consensus EPS estimate for the current year increased 2.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).To break things down more, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 155 individual companies and currently sits at #78 in the Zacks Industry Rank. This group has gained an average of 6.8% so far this year, so AMRX is slightly underperforming its industry in this area. In contrast, Boston Scientific falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #173. Since the beginning of the year, the industry has moved +6.7%.Amneal Pharmaceuticals and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks